title: Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2.
abstract: The prognosis of breast cancer in young women is influenced by reproductive history. Women diagnosed within 5 years postpartum have worse prognosis than nulliparous women or women diagnosed during pregnancy. Here we describe a mouse model of postpartum breast cancer that identifies mammary gland involution as a driving force of tumor progression. In this model, human breast cancer cells exposed to the involuting mammary microenvironment form large tumors that are characterized by abundant fibrillar collagen, high cyclooxygenase-2 (COX-2) expression and an invasive phenotype. In culture, tumor cells are invasive in a fibrillar collagen and COX-2-dependent manner. In the involuting mammary gland, inhibition of COX-2 reduces the collagen fibrillogenesis associated with involution, as well as tumor growth and tumor cell infiltration to the lung. These data support further research to determine whether women at high risk for postpartum breast cancer would benefit from treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) during postpartum involution.
authors.affiliation: Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
authors.forename: Traci R
authors.initials: TR
authors.lastname: Lyons
authors.forename: Jenean
authors.initials: J
authors.lastname: O'Brien
authors.forename: Virginia F
authors.initials: VF
authors.lastname: Borges
authors.forename: Matthew W
authors.initials: MW
authors.lastname: Conklin
authors.forename: Patricia J
authors.initials: PJ
authors.lastname: Keely
authors.forename: Kevin W
authors.initials: KW
authors.lastname: Eliceiri
authors.forename: Andriy
authors.initials: A
authors.lastname: Marusyk
authors.forename: Aik-Choon
authors.initials: AC
authors.lastname: Tan
authors.forename: Pepper
authors.initials: P
authors.lastname: Schedin
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000188:drug therapy / Q000503:physiopathology*; D044584:Carcinoma, Ductal / Q000188:drug therapy / Q000503:physiopathology*; D000068579:Celecoxib; D045744:Cell Line, Tumor; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D004195:Disease Models, Animal; D005260:Female; D024022:Fibrillar Collagens / Q000378:metabolism*; D006801:Humans; D007052:Ibuprofen / Q000494:pharmacology / Q000627:therapeutic use; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D008321:Mammary Glands, Animal / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D051379:Mice; D016513:Mice, SCID; D009361:Neoplasm Invasiveness / Q000503:physiopathology; D049590:Postpartum Period / Q000187:drug effects / Q000502:physiology*; D011247:Pregnancy; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D024022:Fibrillar Collagens; D011720:Pyrazoles; D013449:Sulfonamides; C077623:Ptgs2 protein, mouse; D051546:Cyclooxygenase 2; D000068579:Celecoxib; D007052:Ibuprofen